Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future

Bibliography

• WEISSMAN MM, BLAND RC, CANINO GJ et al: Cross-national epidemiology of major depression and bipolar disorder. JAMA (1996) 276:293–299.
   PubMed Web of Science ®Google Scholar
• MURRRAY CJ, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet (1997) 349:1498–1504.
   PubMed Web of Science ®Google Scholar
• PINT S, PERKONNIG A, TANSELLA M, WITTCHEN HU, PSICH D: Prevalence and 12-month outcome of threshold and subthreshold mental disorders in primary care. Affect. Disord. (1999) 56:37–48.
   PubMed Web of Science ®Google Scholar
• JONES R, YATES WR, WILLIAMS S, ZHOU M, HARDMAN L: Outcome for adjustment disorder with depressed mood: comparison with other mood disorders.' Affect. Disord. (1999) 55:55–61.
   PubMed Web of Science ®Google Scholar
• SIMON GE, VONKORFF M, PICCINELLI M, FULLERTON C, ORIVIEL J: An international study of the relation between somatic symptoms and depression. N Engl. Med. (1999) 341(18):1329–1335.
   PubMed Web of Science ®Google Scholar
• BLAND RC, NEWMAN SC, ORN H: Age and remission of psychiatric disorders. Can.' Psychiatry (1997) 42:722–729.
   PubMed Web of Science ®Google Scholar
• JUDD LL, AKISKAL HS, MASSER JD et al.: A Prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch. Gen. Psychiatry (1998) 55:694–700.
   PubMed Web of Science ®Google Scholar
• GROF P: The age of misery: affective disorders on the rise. Can. .1. Psychiatry (1997) 42:361–362.
   PubMed Web of Science ®Google Scholar
• KUPFER DJ, FRANK E: The interaction of drug- and psychotherapy in the long-term treatment of depression. Affect. Disord. (2001) 62(1-2):131–137.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Essential psychopharmacology Neuroscientific basic and practical applications (2nd edition). Cambridge University Press, Cambridge, UK (2000).
   Google Scholar
• ••An excellent review of current strategies inpsychopharmacology.
   Google Scholar
• THASE ME: The clinical, psychosocial, and pharmacoeconomic ramifications of remission. Am. Manag. Care. (2001) 7\(Supp1.11):5377–5385.
   Google Scholar
• KENNEDY SH, LAM RW, COHEN NL, RAVINDRAN AV, CANMT DEPRESSION WORK: Clinical guidelines for the treatment of depressive disorders: IV Medications and other biological treatments. Can.' Psychiatry (2001) 46\(Suppl. 1):38S–58S.
   Google Scholar
• DONG J, BLIER P: Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (2002) 155(1):52–57.
   Web of Science ®Google Scholar
• BLIER P: Pharmacology of rapid-onset antidepressant treatment strategies. J. Gin. Psychiatry (2001) 62 (Suppl. 15):12–17.
   Google Scholar
• EY AT, RUDOLPH RL, PRESKORN SH: Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry (2000) 57(5):503–509.
   PubMed Web of Science ®Google Scholar
• LINDE K, RAMIREZ G, MULROW CD, PAULS A, WEIDENHAMMER W, MELCHART D: St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ(1996) 313:253–258.
   PubMed Web of Science ®Google Scholar
• GASTER B, HOLROYD J: St John's wort for depression: a systematic review. Arch. Intern. Med. (2000) 160:152–156.
   PubMed Web of Science ®Google Scholar
• HYEPICUM DEPRESSION TRIAL STUDY GROUP: Effect of Hypericum perforatum (St John's wort) in major depression disorder: a randomized controlled trial. JAMA (2002) 287(14):1807–1814.
   PubMed Web of Science ®Google Scholar
• HELTON RC, KELLER MB, GELENBERG A et al.: Effectiveness of St. John's Wort in Major Depression: A randomized controlled trial. JAMA (2001) 285:1978–1986.
   Google Scholar
• ANDERSON IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerabilitiy. Affect. Disord. (2000) 58:19–36.
   PubMed Web of Science ®Google Scholar
• ANDERSON IM, TOMENSEN BM: The efficacy of selective serotonin reuptake inhibitors in depression: A metaanalysis of studies against tricyclic antidepressants. Psychopharmacol (1994) 8:238–249.
   Web of Science ®Google Scholar
• TIGNOL J, STOKER MJ, DUNBAR PG: Paroxetine in the treatment of melancholia and severe depression. mt. Clin. Psychoparmacol (1992) 7:91–94.
   PubMed Web of Science ®Google Scholar
• ANGST J, STABL M: Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology OHL (1992) 106:109S–113S.
   Google Scholar
• WORKMAN EA, SHORT DD: Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J. Clin. Psychiatry (1993) 54:5–12.
   PubMed Web of Science ®Google Scholar
• KASPER S: Clinical efficacy of mirtazapine:a review of meta-analyses of pooled data. hat Clin. Psychopharmacol (1995) 10:25–35.
   PubMed Web of Science ®Google Scholar
• PATTEN SB: The comparative efficacy of trazodone and imipramine in the treatment of depression. CMA 1(1992) 146:1177–1182.
   PubMed Web of Science ®Google Scholar
• SMITH D, DEMPSTER C, GLANVILLEJ, FREEMANTLE N, ANDERSON I: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. Psychiatry (2002) 180:396–404.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, MCCANN SM, MASELLIS M et al.: Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Gin. Psychiatry (2002) 63(3):181–186.
   Google Scholar
• GUELFI JD, ANSSEAU M, TIMMERMAN L, KORSGAARD S, MIRTAZAPINE VENLAFAXINE STUDY GROUP: Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. Clin. Psychopharmacol. (2001) 21(4):425–431.
   PubMed Web of Science ®Google Scholar
• FREEMANTLE N, ANDERSON IM, YOUNG P: Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br. Psychiatry (2000) 177:292–302.
   PubMed Web of Science ®Google Scholar
• BAUER M, DOFMER S: Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. j Clin. Psychopharmacol (2000) 20(2):287.
   PubMed Web of Science ®Google Scholar
• ARONSON R, OFFMAN HJ, JOFFE RT, NAYLOR CD: Triiodothyronine augmentation in the treatment of refractory depression: A meta-analysis. Arch. Gen. Psychiatry (1996) 53:842–848.
   PubMed Web of Science ®Google Scholar
• BAUMANN P, NIL R, SOUHE A et al: Adouble-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J. Clin. Psychopharmacol. (1996) 16:307–314.
   PubMed Web of Science ®Google Scholar
• KATONA CL, ROBERTSON MM, ABOU-SALEH MT et al.: Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. hat. Gin. Pschopharacol. (1993) 8:323.
   PubMed Web of Science ®Google Scholar
• SHELTON RC, TOLLEFSON GD, TOHEN M et al.: A novel augmentation strategy for treating resistant major depression. Am. I Psychiatry(2001) 158:131–134.
   PubMed Web of Science ®Google Scholar
• REIMHERR FW, AMSERDM JD, QUITKIN FM et al.: Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am. .1. Psychiatry (1998) 155:1247–1253.
   Google Scholar
• VIGUERA AC, BALDESSARINI RJ, FRIEDBERG J: Discontinuing antidepressant treatment in major depression. Harv. Res. Psychiatry (1998) 5:293–306.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, LAM RW, COHEN NL, RAVINRRAN AV, CANMAT DEPRESSION WORK GROUP: Clinical guidelines for the treatment of depressive disorders: Medication and other biological treatments. Can. J. Psychiatry (2001) 46\(Suppl. 1):385–585.
   Google Scholar
• KENNEDY SH, EISFELD BS, DICKENS SE, BACCHIOCHI JR, BAGBY PM: Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Clin. Psychiatry(2000) 61:276–281.
   PubMed Web of Science ®Google Scholar
• KARP JF, FRANK E, RITENOUR A, McEACHRAN A, KUPFER DJ: Imipramine and sexual dysfunctioning during the long-term treatment of recurrent depression. Neuropsychopharmacology (1994) 11:21–27.
   PubMed Web of Science ®Google Scholar
• HARRIS B, YOUNG J, HUGHES B: Comparative effects of 7 antidepressant regimes on appetite, weight and carbohydrate preference. Br. .1. Psychiatry (1986) 148:590–592.
   PubMed Web of Science ®Google Scholar
• MONTEJO-GONZALEZ AL, LLORCA G, IZQUIERDO JA et al.: SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 355 patients. Sex Marital Ther. (1997) 23:176–194.
   Google Scholar
• ROSEN RC, LANE RM, MENZA M: Effects of SSRIs on sexual function: a critical review. I Clin. Psychopharmacol (1999) 19:67–85.
   Google Scholar
• COLEMAN CC, CUNNINGHAM LA, FOSTER VJ et al.: Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann. Clin. Psychiatry (1999) 11:205–215.
   PubMedGoogle Scholar
• CROFT H, SETTLE E Jr, HOUSER T, BATEY SR, DONAHUE PM, ASCHER JA: A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Cliii. The]: (1999) 21:643–658.
   PubMed Web of Science ®Google Scholar
• FEIGER A, KIEV A, SHRIVATAVA RK, WISSELINK PG, WILCOX CS: Nefazodone verus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J. Cliii. Psychiatry(1996) 57\(Suppl. 2):53–62.
   Google Scholar
• BOYARSKY BK, HAQUE W, ROULSEA MR, HIRSCHFELD PM: Sexual functioning in depressed outpatients taking mirtazapine. Depress. Anxiety (1999) 9:175–179.
   PubMedGoogle Scholar
• HARRIS B, YOUNG J, HUGHES B: Comparative effects of 7 antidepressant regimes on appetite, weight, and carbohydrate preference. Br. I Psychiatry (1986) 148:590–592.
   PubMed Web of Science ®Google Scholar
• MICHELSON D, AMSTERDAM JD, QUITKIN FM et al.: Changes in weight during a 1-year trial of fluoxetine. Am. J. Psychiatry(1999) 156:1170–1176.
   PubMed Web of Science ®Google Scholar
• FAVA M, JUDGE R, HOOG SL, NILSSON ME, KOKE SC: Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight and long-term treatment. I Clin. Psychiatry (2000) 61:863–867.
   PubMed Web of Science ®Google Scholar
• SUSSMAN N, GINSBERG DL: Weight effects of nefazodone, bupropion, mirtazapine, and venlafaxine: A review of available evidence. Primary Psychiatry (2000) 7:33–48.
   Google Scholar
• FEIGHNER JP, GARDNER EA, JOHNSTON JA et al.: Double-blind comparison of bupropion and fluoxetine in depressed outpatients. I Clin. Psychiatry (1991) 52:329–335.
   PubMed Web of Science ®Google Scholar
• VAZ-SERRA A, FIGUEIRA ML, FIRMINO H, ALBUQUERQUE AJ, JARA JM, PESTANA LC: Multi-center double-blind study of moclobemide and maprotiline. Cliii. Neuropharmacol. (1994) 17\(Supp1.1):38S–49S.
   Google Scholar
• GOODNICK PJ, KREMER C, WINGARD P: Weight change during mirtazapine therapy. Primary Psychiatry (1999) 6:103–108.
   Google Scholar
• STEFFENS DC, KRISHNAN KR, HELMS MJ: Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress. Anxiety (1997) 6:10–18.
   PubMedGoogle Scholar
• ANDERSON IM: SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety (1998) 7:11–17.
   PubMedGoogle Scholar
• MONTGOMERY SA, HENRY J, MCDONALD G et al.: Selective serotonin reuptake inhibitors: a meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol (1994) 9:47–53.
   PubMed Web of Science ®Google Scholar
• HIGLEY JD, KING ST Jr, HASERT ME CHAMPOUX M, SUOMI SJ, LINNOILA M: Stability of interindividual differences in serotonin function and its relationship to severe aggression and competent social behavior in rhesus macaque females. Neuropsychopharmacology (1996) 14:67–76.
   PubMed Web of Science ®Google Scholar
• ••An interesting report of the relationship between 5-HT, aggression and social behaviour in vervet monkeys.
   Google Scholar
• KNUTSON B, WOLKOWITZ OM, COLE SW et al.: Selective alteration of personality and social behavior by serotonergic intervention. Am. I Psychiatry (1998) 155:373–379.
   PubMed Web of Science ®Google Scholar
• ••A very interesting article describing theeffects of paroxetine versus placebo on psychiatrically healthy volunteers. SSRI administration led to a decrease in negative affect but did not alter positive affect, as well as an increase on a behavioural index of affiliation, with affiliation correlating r = 0.65 with plasma paroxetine levels.
   Google Scholar
• ZOHAR J, MUELLER EA, INSEL TR et al.: Serotonergic responsivity in obsessive compulsive disorder: comparison of patients and healthy controls. Arch. Gen. Psychiatry (1987) 44:946–951.
   PubMed Web of Science ®Google Scholar
• KENNET GA, LIGHTOWLER S, DeBIASI V et al.: Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT-2B receptor function. Neuropharmacology (1994) 12:1581–1588.
   Web of Science ®Google Scholar
• SKREBUHHOVA T, ALLIKMERTS L, MATTO V: 5-HT2Areceptors mediate the effects of antidepressants in the elevated plus-maze test but have a partial role in the force swim test. Med. Sci. Res. (1999) 27:277–280.
   Google Scholar
• MANN JJ: The neurobiology of suicide. Nat. Med. (1998) 4:25–30.
   PubMed Web of Science ®Google Scholar
• DU L, BAKISH D, LAPIERRE YD et al.: Assocation of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Jim. .1 Med. Genetics (2002) 96:56–60.
   Google Scholar
• GRAEFF FG, GUIMARAES FS, DE ANDRADE GCS, DEAKIN JEW: Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem. Behav. (1996) 54(1):129–141.
   PubMed Web of Science ®Google Scholar
• DREVETS WC, THASE M, FRANK E, PRICE JC, MATHIS C, KUPFER DJ: Serotonin type-1A receptor imaging in unipolar and bipolar depression. Socieg, of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):102S (Abstract).
   Google Scholar
• AUERBACH SB, HJORTH S: Effects of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain M vivo. Naun-Schmid Arch. Pharmacol (1995) 352:597–606.
   PubMed Web of Science ®Google Scholar
• ROMERO L, BEL N, ARTIGAS F et al:Effect of pindolol on the function of pre-and post synaptic 5-HTiAreceptors: in vivo microdialysis and electrophysiological studies in rat brain. Neuropsychopharmacology (1996) 15:349–360.
   PubMed Web of Science ®Google Scholar
• DOURISH CT, HUTSON PH, CURZON G: Putative anxiolytics 8-0H-DPAT, busprione and TVXQ7821 are agonists at 5-HTiA autoreceptors in the raphe nuclei. Trends Pharmacol Sci. (1986) 6:212–214.
   Web of Science ®Google Scholar
• MATZEN L, VAN AMSTERDAM C, RAUTENBERG W et al.: 5-HT1gm antagonistic activity: a new approach toward efficient antidepressants. I Med. Chem. (2000) 43:1149–1157.
   PubMed Web of Science ®Google Scholar
• BONAVENTURE P, LANGLOIS X, LEYSEN JE: Co-localisation of 5-HT1B and 5-HT1D receptor mRNA in serotonergic cell bodies in guinea-pig dorsal raphe nucleus: a double labeling in situ hybridization histochemistry study. Neurosci. Lett. (1998) 254:113–116.
   PubMed Web of Science ®Google Scholar
• DAVIDSON C, STAMFORD JA: Evidence that 5-HT release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5 -HTig and 5 -HT1D autoreceptors. Br. Pharmacol (1995) 114:1107–1109.
   PubMed Web of Science ®Google Scholar
• OLIVER KR, KINSEY AM, WAINWRIGHT A et al.: Localisation of 5-HT5Areceptor-like immunoreactivity in the rat brain. Brain Res. (2000) 867:131–142.
   PubMedGoogle Scholar
• DUNCAN MJ, JENNES L, JEFFERSON JB et al.: Localization of serotoning, receptors in discrete regions of the circadian timing system in the Syrian hamster. Brain Res. (2000) 869:178–185.
   PubMed Web of Science ®Google Scholar
• WOOD MD, THOMAS DR, WATSON JM: Therapeutic potential of serotonin antagonists in depressive disorders. Expert Opin. Investig. Drugs (2002) 11(4):457–467.
   PubMed Web of Science ®Google Scholar
• NEUMAIER JF, SEXTON TJ, YRACHETA Y, eta: Localization of 5-HT7 receptors in rat brain by immunocytochemisty in situ hybridization, and agonist stimulated cFos expression. Chem. Neuroanal (2000) 31:284–314.
   Google Scholar
• GANNON RL: 5-HT7receptors in rodent suprachiasmatic nucleus. Biol. Rhythm (2001) 16:19–24.
   PubMed Web of Science ®Google Scholar
• BRUNELLO N, ARMITAGE R, FEINBERG I et al.: Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology (2000) 42:107–119.
   PubMed Web of Science ®Google Scholar
• RESSLER KJ, NEMEROFF C: Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry (1999) 46(9):1219–1233.
   PubMed Web of Science ®Google Scholar
• FLOGGE G, AHRENS 0, FUCHS E: Monoamine receptors in the prefrontal cortex of tupaia belangeri during chronic psychosocial stress. Cell Tissue Res. (1997) 288:1–10.
   PubMed Web of Science ®Google Scholar
• FULFORD AJ, MARSDEN CA: Effects of isolation-rearing on noradrenaline release in rat hypothalamus and hippocampus M vitro. Brain Res. (1997) 748:93–99.
   PubMed Web of Science ®Google Scholar
• GARCIA-VALLEJO P, GOMEZ FM, INFANTE C, GINESTAL E, GIRALT MT: chronic variable stress induces supersensitivity of central a2-adrenoceptors which modulate the jaw-opening reflex in the rat. Brain Res. (1998) 801:72–77.
   PubMed Web of Science ®Google Scholar
• GRANT KA, SHIVELY CA, NADER MA et al.: Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse (1998) 29:80–83.
   PubMed Web of Science ®Google Scholar
• ••This article presents evidence that socialstatus in cynomolgus monkeys is associated with striatal D2 receptor binding.
   Google Scholar
• DEPUE RA, LUCIANA M, ARBISI P, COLLINS P, LEON A: Dopamine and the structure of personality: Relation of agonist-induced dopamine activity to positive emotionality. Pers. Soc. Psycho]. (1994) 67:485–498.
   PubMed Web of Science ®Google Scholar
• ••Modern trait theories of personalityinclude a dimension reflecting positive emotionality (PE) based on sensitivity to signals of incentive-reward. Results presented in this article suggest that PE may be related to individual differences in dopamine functioning.
   Google Scholar
• CONTRERAS-VIDAL JL, SCHULTZ W: A predictive reinforcement model of dopamine neurons for learning approach behavior. Comput. Neurosci. (1999) 6:191–214.
   PubMed Web of Science ®Google Scholar
• KOOB GF: Hedonic valence, dopamine and motivation. Ma Psychiatry(1996) 1:186–189.
   Google Scholar
• DI MATTEO V, DI MASCIO M, DI GIOVANNI G, ESPOSITO E: Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors. Psychopharmacology OHL (2000) 150(1):45–51.
   PubMed Web of Science ®Google Scholar
• WYVELL CL, BERRIDGE KC: Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward 'wanting' without enhanced 'liking' or response reinforcement. Neurosci. (2000) 20(21):8122–8130.
   PubMed Web of Science ®Google Scholar
• CORRIGAN MH, DENAHAN AQ, WRIGHT CE, RAGUAL RJ, EVANS DL: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety (2000) 11(2):58–65.
   PubMed Web of Science ®Google Scholar
• TASSIN JP, DARRACQ L, BLANC G, TROVERO F: Integrating the monoamine systems In: Antidepressant Therapy at the Dawn of the Third Millennium. M Brierley, S Montgomery (Eds), Martin Dunitz (1998):1–18.
   Google Scholar
• MANJI HK, LENOX RH: Signaling: Cellular insights into the pathophysiology of bipolar disorder. Biol. Psych. (2000) 48:518–530.
   PubMed Web of Science ®Google Scholar
• MANJI HK, MOORE GJ, RAJKOWSKA G, CHEN G: Neuroplasticity and cellular resilience in mood disorders. Millennium articles. Ma Psychiatry (2000) 5:578–593.
   Google Scholar
• LOPEZ JF, CHALMERS DT, LITTLE KY,WATSON SJ: Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry (1998) 43:547–573.
   PubMed Web of Science ®Google Scholar
• BLIER P, DeMONTIGNY C: Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology (1999) 21:91S–98S.
   Google Scholar
• DUNMAN RS: Synaptic plasticity and mood disorders. Ma Psychiatry(2002) 7\(Suppl. 7):S29–S34.
   Google Scholar
• MANJI HK, DREVETS WC, CHARNEY DS: The cellular neurobiology of depression. Nat. Med. (2001) 7:541–547.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB: The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Ma Psychiatry(1996) 1:336–342.
   Google Scholar
• FUCHS E, KRAMER M, HERMES B, NETTER B, HIEMKE C: Psycholosocial stress in tree shrews: clomipramine counteracts behavioural and endocrine changes. Pharmacol Biochem. Behav. (1996) 54:219–228.
   PubMed Web of Science ®Google Scholar
• SCHMIDT LA, FOX NA, RUBIN KH et al.: Behavioral and neuroendocrine responses in shy children. Dev. Psychobiol (1997) 30:127–140.
   PubMed Web of Science ®Google Scholar
• ROSEN JB, SCHULKIN J: From normal fear to pathological anxiety. Psycho]. Rev (1998) 105(2):325–350.
   PubMed Web of Science ®Google Scholar
• SULLIVAN GM, COPLAN JD, KENT JM, GORMAN JM: The nomdrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol. Psychiatry (1999) 46:1205–1218.
   PubMed Web of Science ®Google Scholar
• SAPOLSKY RM: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry(2000) 57:925–935.
   PubMed Web of Science ®Google Scholar
• REUS VI, WOLKOWITZ OM: Antiglucocorticoid drugs in the treatment of depression. Expert. Opin. filvestig. Drugs (2001) 10(1):1789–1796.
   PubMedGoogle Scholar
• DREVETS WC: Neuroimaging studies of mood disorders: Implications for a neural model of major depression. Biol. Psychiatry (2000) 48:813–829.
   PubMed Web of Science ®Google Scholar
• DREVETS WC, GADDE, K, KIRSHNAN R: Neuroimaging studies of depression. In: Neurobiology of Mental Illness. DS Charney, EJ Nester, BS Bunney (Eds), Oxford Press, New York (1999):394–418.
   Google Scholar
• RAJKOWSKA G, MIGUEL-HIDALGO JJ, WEI J et al.: Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry (1999) 45:1085–1098.
   PubMed Web of Science ®Google Scholar
• ONGOR D, DREVETS WC, PRICE JL: Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Nat. Acad. Sci. USA (1998) 95:13290–13295.
   PubMed Web of Science ®Google Scholar
• BRAMBILLA P, NICOLETTI MA, SASSI RB et al.: Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar disorder patients. Socieg, of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):138S (Abstract).
   Google Scholar
• BOWLEY MP, DREVETS WC, ONGOR D, PRICE JL: Low Glial numbers in the amygdala and entorphinal cortex in mood disorders. Society of Biological Psychiatry 57th Annual Convention and Scientific Program. Philadelphia, USA (2002):97S (Abstract).
   Google Scholar
• LOSIFESCU DV, RENSHAW PF, LY00 IK, LEE HK, FAVA M: Brain MRI white matter hyperintensities correlate with improved treatment outcome in depression. Society of Biological Psychiatry 57th Annual Convention and Scientific Program. Philadelphia, USA (2002):1085 (Abstract).
   Google Scholar
• COYLE JT, SCHWARCZ R: Mind glue: implications of glial cell biology for psychiatry. Arch. Gen. Psychiatry (2000) 57:90–93.
   PubMed Web of Science ®Google Scholar
• TREVOR LT, BAKISH D, BEAULIEU S: The neurobiology of treatment response to antidepressants and mood stabilizing medications. J. Psychiatry Neurosci. (2002) 27(4):260–265.
   PubMed Web of Science ®Google Scholar
• DREVETS W: Neuroimaging and neuropathological studies of depression: Implications for the cognitive emotional manifestations of mood diosorders. Curi: Opin. Neurobiol (2001) 11:240–249.
   PubMed Web of Science ®Google Scholar
• BAXTER LRJ: Neuroimaging studies of obsessive compulsive disorder. Psychiatr. Clin. North Am. (1992) 15:871–884.
   PubMed Web of Science ®Google Scholar
• SWEDO SE, PIETRINI P, LEONARD HL et al.: Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch. Gen. Psychiatry (1992) 49:690–694.
   PubMed Web of Science ®Google Scholar
• INSEL TR: Toward a neuroanatomy of obsessive-compulsive disorder. Arch. Gen. Psychiatry (1992) 49:739–744.
   PubMed Web of Science ®Google Scholar
• MCEWENS BS: Stress and Hippocampal plasticity. Ann. Rev. Neurosci (1999) 22:105–122.
   PubMed Web of Science ®Google Scholar
• BROWN ES, RUSH AJ, MCEWEN BS: Hippocampal remodelling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology (1999) 21:474–484.
   PubMed Web of Science ®Google Scholar
• SONINO N, FAVA GA: Psychosomatic aspects of Cushing's disease. Psychother: Psychosom. (1998) 67:140–146.
   PubMed Web of Science ®Google Scholar
• STARKMAN MN, GIORDANI B, GEBARSKI SS, BERENT S, SCHORK MA, SCHTEINGART DE: Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol. Psychiatry(1999) 46:1595–1602.
   PubMed Web of Science ®Google Scholar
• BLACK IB: Trophic regulation of synaptic plasticity. J. Neurobiol (1999) 41:108–118.
   PubMedGoogle Scholar
• BONNI A, BRUNET A, WEST AE, DATTA SR, TAKASU MA, GREENBERG ME: Cell survival promoted by the Ras-MAPK signalling pathway by transcription-dependent and independent mechanisms. Science (1999) 286:1358–1362.
   PubMed Web of Science ®Google Scholar
• FINKBEINER S: CREB couples neurotrophin signals to survival messages. Neuron (2000) 25:11–14.
   PubMed Web of Science ®Google Scholar
• ADAMS JM, CORY S: The Bci-2 protein family: arbiters of cell survival. Science (1998) 281:1322–1326.
   PubMed Web of Science ®Google Scholar
• DUMAN RS, MALBERG J, NAKAGAWA S, D'SA C: Neuronal plasticity and survival in mood disorders. Biol. Psychiatry (2000) 48:732–739.
   PubMed Web of Science ®Google Scholar
• ••An excellent recent review of the role ofneuronal plasticity in mood disorders.
   Google Scholar
• GOULD E, TANAPAT P, RYDEL T, HASTINGS N: Regulation of hippocampal neurogenesis in adulthood. Biol. Psychiatry (2000) 48:715–720.
   PubMed Web of Science ®Google Scholar
• GOULD E, REEVES AJ, GRAZIANO MS, GROSS CG: Neurogenesis in the neocortex of adult primates. Science (1999) 286:548–552.
   PubMed Web of Science ®Google Scholar
• VINET J, BERNIER PJ, PARENT A: Bc1-2 expression in thalamus, brainstem, cerebellum and visual cortex of adult primate. Neurosci. Res. (2002) 42(4):269–277.
   PubMed Web of Science ®Google Scholar
• PARIANTE CM, MAKOFF A, KERWIN RW: Antidepressants increase intracellular concentration of cortisol by modulating a membrane steroid transporter. Socieg, of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):44S (Abstract).
   Google Scholar
• JACOBS BL, PRAAG H, GAGE FH: Adult brain neurogenesis and psychiatry: a novel theory of depression. Ma Psychiatry (2000) 5:262–269.
   Google Scholar
• MANJI HK, DREVET WC, CHARNEY DS: The cellular neurobiology of depression. Nat. Med. (2001) 7:541–547.
   PubMed Web of Science ®Google Scholar
• ••An excellent recent review of currentresearch and evidence regarding the neurobiology of depression.
   Google Scholar
• MALBERG JE, EISCH AJ, NESTLER EJ, DUMAN RS: Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.j. Neurosci. (2000) 20:9104–9410.
   PubMed Web of Science ®Google Scholar
• ZHOU R, DAMSCHRODER-WILLIAMS PJ, YUAN P, CHEN G, MANJI HK: Valproate, an anticonvulsant and mood-stabilizing agent suppresses death genes and induces cell survival genes. Society of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):185S (Abstract).
   Google Scholar
• NEMETS B, MISHORY A, LEVINE J, BELMAKER RH: Inositol addition does not improve depression in SSRI treatment failures. I Neural. Transm. (1999) 106(7-8):795–798.
   PubMed Web of Science ®Google Scholar
• LLOYD KG, ZIVKOVIC B, SCATTON B, MORSELLI PL, BARTHOLINI G: The gabaergic hypothesis of depression. Prog. Neuropsychopharmacol Biol. Psychiatry (1989) 13(3-4):341–351.
   PubMed Web of Science ®Google Scholar
• GUIDOTTI A, COSTA E: Can the antidysphoric and amdolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-terahydorprogesterone (allopregnanolone) availability? Biol. Psychiatry (1998) 44(9):865–873.
   Web of Science ®Google Scholar
• NOWAK G, TRULLAS R, LAYER RT, SKOLNICK P, PAUL IA: adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. Pharmacol Exp. Ther. (1993) 265:1380–1386.
   PubMed Web of Science ®Google Scholar
• MURPHY DL, MITCHELL PB, POTTER WZ: Novel pharmacological approaches to the treatment of depression. In: Psychopharmacology: the Fourth Generation of Progress. FE Bloom, DJ Kupfer (Eds), Raven Press, New York, USA (1995):1143–1153.
   Google Scholar
• GEWIRTZ JC, CHEN AC, TERWINLLIGER R, DUNMAN RC, MAREK GJ: Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem. Behav. (2002) 73(2):317–326.
   PubMed Web of Science ®Google Scholar
• SIMMONS RM, WEBSTER AA, KALRA AB, IYENGAR S: group II mGlu receptors agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem. Behav. (2002) 73(2):419–427.
   PubMed Web of Science ®Google Scholar
• ROBBED, ALONSA G, CHAUMONT S, BOCKAERT J, MANZONI 0J: Role of p/ q-Ca2+ channels in metabotropic glutamate receptor 2/3-dependent presynaptic long-term depression at nucleus accumbens synapses. Neurosci. (2002) 22(11):4346–4356.
   PubMed Web of Science ®Google Scholar
• LIU F, VIRSHUP DM, NAIRN AC, GREENGARD P: Mechanisms of regulation of casein kinase I activity by group I metabotropic glutamate receptors. J. Biol. Chem. (2002) 277(47)45393–45399.
   Google Scholar
• SVENNINGSSON P, TZAVARA ET, LIU F, FIENBERG AA, NOMIKOS GG, GREENGARD P: DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc. Natl. Acad. Sri. USA (2002) 99(5):3188–3193.
   PubMed Web of Science ®Google Scholar
• SVENNINGSSON P, TZAVARA ET, WITKIN JM, FIENBERG AA, NOMIKOS GG, GREENGARD P: Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA (2002) 99(5):3182–3187.
   PubMed Web of Science ®Google Scholar
• SARIA A: The tachyldnin NKi receptor in the brain: pharmacology and putative functions. Eur. Pharmacol (1999) 375:51–60.
   PubMed Web of Science ®Google Scholar
• REGOLI D, BOUDON A, FAUCHERE JL: Receptors and antagonists for substance P and related peptides. Pharmacol Rev (1994) 46:551–599.
   PubMed Web of Science ®Google Scholar
• OTSUKA M, YOSHIOKA K: Neurotransmitter functions of mammalian tachykinins. Physiol Rev (1993) 73:229–308.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281(5383):1640–1645.
   PubMed Web of Science ®Google Scholar
• TATEMOTO K, CARLQUIST M, MUTT V: Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (1982) 296(5858):659–660.
   PubMed Web of Science ®Google Scholar
• GRAY TS, MORLEY JE: Neuropeptiede Y: anatomical distribution and possible function in mammalian nervous system. Life Sci. (1986) 38:389–401.
   PubMed Web of Science ®Google Scholar
• BOULENGER JP, JERABEC I, JOLICOEUR FB, LAVALLEE YJ, LEDUC R, CADIEUX A: Elevated plasma levels of neuropeptide Y in patients with panic disorder. AmJ Psychiatry (1996) 153:114–116.
   PubMed Web of Science ®Google Scholar
• CABERLOTTO L, HURD YL: Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. Neuropsychopharmacology (2001) 25(1):91–97.
   Google Scholar
• REDROBE JP, DUMONT Y, FOURNIER A, QUIRION R: The neuropeptide Y(NPY) receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology (2002) 26(5):615–624.
   PubMed Web of Science ®Google Scholar
• MAKINO S, BAKER RA, SMITH MA, GOLD PW: differential regulation of neuropeptide Y mRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants. Neuroendocrinol (2000) 12:387–395.
   Web of Science ®Google Scholar
• CABERLOTTO L, JIMENEZ P, OVERSTREET DH, HURD YL, MATHE AA, FUXE K: Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. Neurosci. Lett. (1999) 265:191–194.
   PubMed Web of Science ®Google Scholar
• HUSUM H, MIKKELSEN JD, HOGG S, MATHE AA, MORK A: Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuopharmacology (2000) 39:1463–1473.
   PubMed Web of Science ®Google Scholar
• MADSEN TM, GRISEN MH, NIELSEN SM, BOLWIG TG, MILKKELSEN JD: Electroconvulsive stimuli enhance both neuropeptide Y receptor Y1 and Y2 messenger RNA expression and levels of binding in the rat hippocampus. Neuroscience (2000) 98:33–39.
   PubMed Web of Science ®Google Scholar
• MATHE AA, JIMENEX PA, THEODORSSON E, STENFORS C: Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded 'depressed' Winstar, and Sprague-Dawley rats. Effects of electroconvulsive stimuli. Frog. Neuropsychopharmacol Biol. Psychiatry (1998) 22:529–546.
   PubMed Web of Science ®Google Scholar
• ROQUES BP: Novel approaches to targeting neuropeptide systems. Trends Pharmacol Sci. (2000) 21(12):475–483.
   PubMed Web of Science ®Google Scholar
• HORROBIN DF: Phosphofipid metabolism and depression: the possible roles of phospholipase A2 and Coenzyme A-independent Transacylase. Hum. Psychopharmacol (2001) 16:45–52.
   PubMed Web of Science ®Google Scholar
• LOCKE CA, STOLL AL: Omega-3 fatty acids in major depression. World Rev Nutr. Diet (2001) 89:173–185.
   PubMedGoogle Scholar
• HALARIS A, PILETZ JE: Imidazoline receptors: possible involvement in the pathophysiology and treatment of depression. Hum. Psychopharmacol (2001) 16:65–69.
   PubMed Web of Science ®Google Scholar
• COPLAN JD, LYDIARD RB: The Neurobiology of Anxiety Disorders: Brain Circuits in Panic Disorder. Biol. Psychiatry (1998) 44:1264–1276.
   PubMed Web of Science ®Google Scholar
• MEYER JH, KAPUR S, EISFELD B et al: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F] setoperone PET imaging study. Am. Psychiatry (2001) 158(1):78–85.
   PubMed Web of Science ®Google Scholar
• VIDEBECH P, PETERSEN TH: Depression, stress and brain function. Ugeskr. Laeger (2001) 163(47):6568–6572.
   PubMed Web of Science ®Google Scholar
• VIDEBECH P, RAVNKILDE B, PEDERSEN AR, EGANDER A, LANDBO B, RASMUSSEN NA: The Danish PET/depression project: PET findings in patients with major depression. Pssychol Med. (2001) 31(7):1147–1158.
   PubMed Web of Science ®Google Scholar
• GRAY JA: The Neuropsychology of Anxiety (1st edition), Oxford University Press, Oxford, UK (1982).
   Google Scholar
• CLONINGER CR: The genetics and psychobiology of the seven-factor model of personality. In: Biology of Personality Disorders. KR Silk (Ed.), American Psychiatric Press, Washington, USA (1998):63–92.
   Google Scholar
• HARRO J, ORELAND L: Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res. Rev. (2001) 38:79–128.
   PubMed Web of Science ®Google Scholar
• PRZYBYSLAWSKY J, ROULLET P, SARA SJ: Attenuation of emotional and nonemotional memories after their reactivation: role of 13 adrenergic receptors. Neurosci. (1999) 19:6623–6628.
   PubMed Web of Science ®Google Scholar
• SWEATT JD: The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. Neurochem. (1999) 76:1–10.
   Web of Science ®Google Scholar
• SHELINE YI, SANGHAVI M, MINTUN MA, GADO MH: Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. Neurosci. (1999) 19(12):5034–5043.
   PubMed Web of Science ®Google Scholar
• MINER CM, BROWN EB, GONZALES JS, MUNIR R: Switching from daily SSRIs to Fluoxetine once-weekly. Socieg, of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):315 (Abstract).
   Google Scholar
• BURKE WJ, GERGEL I, BOSE A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Clin. Psychiatry (2002) 63(4):331–336.
   PubMed Web of Science ®Google Scholar
• MARAZZITI D, PALEGO L, GIROMELLA A et al.: Region-dependent effects of flibanserin and bupirone on adenylyl cyclase activity in the human brain. Int. J. Neuropsychopharmacol (2002) 5(2):131–140.
   PubMed Web of Science ®Google Scholar
• ••This is an extremely interesting report thatsuggests the possibility of developing pathway specific agents.
   Google Scholar
• GIBERTINI M, FEIGER AD, HEISER JF et al.: Gepirone extended-release (ER): New evidence for efficacy in the treatment of major depressive disorder. Socieg, of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):415 (Abstract).
   Google Scholar
• BASF to merge Boots Pharma under Knoll name. Scrip (1995) 2014:10.
   Google Scholar
• COSTALL B, DOMENY AM, FARRE AJ, KELLY ME, MARTINEZ L, NAYLOR W: Profile of action of a ovel 5-hydroxytryptamine lA receptor ligand E-4424 to inhibit aversive behaviour in the mouse, rat and marmoset. J. Pharmacol Exp. Ther. (1992) 262(1):90–98.
   PubMed Web of Science ®Google Scholar
• DEKEYNE A, BROCCO M, ADHUMEAU A et al.: The selective serotonin (5-HTIA) receptor ligand, S15535, displays amdolytic-like effects in the social interaction and vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. Psychopharmacology (2000) 152:55–66.
   PubMed Web of Science ®Google Scholar
• MURCK H, HELD K, FRIEBOES RM et al.: Fast adaptive changes of the sleep regulatory system after a single dose of putative antidepressive substance EMD 68843. Int. J. Neuropsychpharmacol (2000) 3:197.
   Google Scholar
• ROBERTS C, WATSON J, PRICE GW, MIDDLEMISS DN: SB-236057-A: a selective 5-HTIB receptor inverse agonist. CNS Drug Rev. (2001) 7(4):433–444.
   PubMedGoogle Scholar
• SPROUSE J, BRASELTON J, REYNOLD L: 5-HT(1A) agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus. Biol. Psychiatry (2000) 47(12):1050–1055.
   PubMed Web of Science ®Google Scholar
• JOHANSSON L, SOHN D, THORBERG S-0 et al.: The pharmacological characterisation of novel selective 5-hydroxytrptamine la receptor antagonist, NAD-299. Pharmacol Exp. Ther. (1997) 283:216–225.
   Google Scholar
• MOS H, VANHEST A, VANDRIMMELEN M et al.: The putative 5-HTiA receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HTiAreceptor agonist flesinoxan in pigeons. Eur. Pharmacol (1997) 325:145–153.
   PubMed Web of Science ®Google Scholar
• SILVESTRE J, GRAUL A, CASTANER J: Sunepitron hydrochloride. Drugs Future (1998) 23:161–165.
   Google Scholar
• JORGENSEN H, KJAER A, WARBERGJ, KNIGGE U: Differential effect of serotonin 5-HT(1A) receptor antagonists on the secretion of corticotropin and prolactin. Neuroendocrinology (2001) 73(5):322–333.
   PubMed Web of Science ®Google Scholar
• ROBERTS C, PRICE GW, MIDDLEMISS DN: Ligands for the investigation of 5-HT autoreceptor function. Brazil Res. Bull. (2001) (5):463–469.
   Google Scholar
• SLASSI A: Recent advances in 5-HT 1B/1D receptor antagonists and agonists and their potential therapeutic applications. Carr: Top Med. Chem. (2002) 2(6):559–574.
   PubMedGoogle Scholar
• BONAVENTURE P, LAN GLOIS Y, LEYSEN JE: Co-localisation of 5-HT1B and 5-HT1D receptor Mrna in serotonergic cell bodies in guinea-pig dorsal raphe nucleus: a double labelling in situ hybridization histochemistry study. Neuropharmacology (1998) 34:377–382.
   Google Scholar
• STARKEY SJ, SKINGLE M: 5-HT1D as well as 5-HTlAautoreceptors modeulate 5-HT release in guinea-pig dorsal raphe nucleus. Neuropharmacology (1994) 33:393–402.
   PubMed Web of Science ®Google Scholar
• NARAYAN M, ANDERSEN G, CELLAR J, MALLISON RT, PRICE LH, NELSON JC: Serotonin transporter-blocking properties of nefazodone assessmed by measurement of platelet serotonin. Clio. Psychopharmacol (1998) 18:67–71.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WHM, SEYMOUR H, OKIN S et al.: Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J. Clio. Pharmacol (1995) 35(6):541–572.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology (1999) 21(2S):106S–115S.
   Google Scholar
• HOECHST MARION ROUSSEL AG: Hoechst Marion Roussel announces second quarter results. (4 August, 1999) (Press release).
   Google Scholar
• BORSINI F, CESANA R: Further characterization fo potential antidepressant action of flibanserin. Psychopharmacology (lier) (2001) 59(1):64–69.
   Google Scholar
• WOOD MD, REAVILL C, TRAIL B et al: SB-243213; a selective 5-HT2c receptor inverse agonist with improved amdolytic profile: lack of tolerance and withdrawal anxiety. Neuropsychopharmacology (2001) 41(2):186–199.
   Google Scholar
• DiMATTE0 V, Di GIOVANNI G, ESPOSITO E: SB 242084: a selective 5-HT2c receptor antagonist. CNS Drug Rev (2000) 6:195–205.
   Google Scholar
• Egis' Tensiomin tops Hungarian sales. Scrip (1996): 2138:8.
   Google Scholar
• JENCK F, MOREAU JL, WICHMANN J, STADLER H, MARTIN JR, BOS M: Brain 5-HT2c receptors: potential role in anxiety disorders. In: Anxiolytics: Milestones in Drug Therapy M Briley, D Nutt (Ms), Birkhäuser Verlag AG, Switzerland (2000).
   Google Scholar
• WAGSTAFF AJ, ORMROD D, SPENCER CM: Tianeptine: a review of its use in depressive disorders. CNS Drugs (2001) 15(3):231–259.
   PubMed Web of Science ®Google Scholar
• DZIEDZICKA-WASYLEWSKA M, DLABOGA D, PIERZCHALA-KOZIEC K, ROGOZ Z: Effect of tianeptine and fluoxetine on the levels of Met-enkephalin and mRNA encoding proenkephalin in the rat.' Psychiol Pharmacol (2002) 53(1):117–125.
   Google Scholar
• GOLDSTEIN DJ, YILI L, DETKE M, WILTSE C, MALLINCKRODT C, DEMITRACK MA: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Society of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):1235 (Abstract).
   Google Scholar
• MOCAER E, PAPP M, GRUCA P: The antidepressant activity of S 20098 (Agomelatine) in chronic mild stress is related to both its melatonin agonist and 5-HT2C antagonist properties. XX/// Collegium International Nemo-Psychopharmacologium (CINP) Congress, Montreal, Canada (2002): E. MOCAER2 (Abstract).
   Google Scholar
• JOBERT M, JAHNIG P, SCHULZ H: Effect of two antidepressant drugs on REM sleep and EMG activity during sleep. Neuropsychobiology (1999) 39(2):101–109.
   PubMed Web of Science ®Google Scholar
• PRETTI A: Tomoxetine (Eli Lilly & CO). Curt Opin. Investig. Drugs (2002) 3(2):272–277.
   PubMedGoogle Scholar
• GIBBS ME, SUMMERS RJ : Enhancement of memory consolidation in chicks by beta (3)-adrenoceptor agonists. Eur. Pharmacol (2001) 413(2-3):235–240.
   PubMed Web of Science ®Google Scholar
• SIMIAND L, KEANE PE, GUITARD J et al.: Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical P-adrenoceptors. Eat Pharmacol (1992) 219(2):193–201.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Classical antidepresssants, serotonin selective reuptake inhibitors and noradrenergic reuptake inhibitors. In: Essential Psychopharmacology (2nd Edition). SM Stahl (Ed.), Cambridge University Press, Cambridge, UK (2000):199–243.
   Google Scholar
• EMMANUEL NP, LYDIARD RB, BALLENGER JC: Treatment of social phobia with bupropion (letter). Clio. Psychopharmacol (1991) 11:276–277.
   PubMed Web of Science ®Google Scholar
• EDWARDS JG, DINAN TG, WALLER DG, GREENTREE SG: Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline. Bt.). Clio. Pharmacol (1996) 42(4):491–498.
   PubMed Web of Science ®Google Scholar
• WILINER P: The mesolimbic dopamine system as a target for rapid antidepressant action. hat Clio. Psychopharmacol. (1997) 12\(Suppl. 3):57–514.
   Google Scholar
• NIERENBERG AA, DOUGHERTY D, ROSENBAUM IF: Dopaminergic agents and stimulants as antidepressant augmentation strategies. I Clio. Psychiatry (1998) 59\(Suppl. 5):60–63.
   Google Scholar
• HADDAD P: Do antidepressants have any potential to cause addiction? Psychopharmacol. (1999) 13(3):300–307.
   Google Scholar
• VILLARREAL G, JOHNSON MR, RUBEY R, LYDIARD RB, BALLANGER IC: Treatment of social phobia with the dopamine agonist pergolide. Depress. Anxiety (2000) 11:45–47.
   PubMed Web of Science ®Google Scholar
• ANDREE B, HALLDIN C, DEVRIESM V, FARDE L: Central 5-HT 2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (1997) 131:339–345.
   PubMed Web of Science ®Google Scholar
• ROCCA P, FONZO V, RAVIZZA L et al: A comparison of paroxetine and amisulpride in the treatment of dysthmic disorder. I Affect. Disord. (2002) 70(3):313–317.
   PubMed Web of Science ®Google Scholar
• AMSTERDAM JD, BODKIN JA: Transdermal selegiline in the treatment of patients with major depression: A double-blind placebo-controlled trial. Meeting of the 40th Annual New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, USA (2000):15 (Abstract).
   Google Scholar
• GRIEBEL G, SIMIAND J, SERRADEIL-LE GC et al.: Amdolytic- and antidepressant-like effects of the non-peptide vasopressin V lb receptor antagonist, SSRI 49415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA (2002) 99:6370–6375.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G: Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Then. (1999) 82:1–61.
   Google Scholar
• ••An excellent review of the potential for neuropeptide receptor ligands in the treatment of anxiety disorders.
   Google Scholar
• CHRISTOS TE, ARVANITIS A: Corticotrophin-releasing factor receptor antagonists. Expert Opin. Then. Patents (1998) 8:143–152.
   Web of Science ®Google Scholar
• ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormibe receotir 1 antagonist R121919 in major deoressuib: the first 20 patients treated.' Psychiatr. Res. (2000) 34(3):171–181.
   Google Scholar
• SCHULZ DW, MANSBACH RS, SPROUSE J et al: CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Nati Acad. Sci. USA (1996) 93:10477–10482.
   PubMed Web of Science ®Google Scholar
• NEUROCRINE BIOSCIENCES INC: Neurocrine announces that Janssen Pharmaceutica intends to replace R121919 with a back-up compound - Neurocrine CRF program on track for Phase Itrials to begin 2nd half 2000 with unpartnered CRF antagonist compound for anxiety/ depression. (5 April, 2000) (Press release).
   Google Scholar
• OWENS MI, NEMEROFF CB: Corticotropin-releasing factor antagonists in affective disorders. Expert. Opin. Ivestig. Drugs (1999) 8:1849–1858.
   PubMedGoogle Scholar
• WONG M-L, WEBSTER EL, SPOKES H et al.: Chronic administration of the non-petite CRH Type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life ScL (1999) 65:PL53-PL58.
   Google Scholar
• GREIBEL G, SIMIAND J, STEINBERG R et al.: 4-(2-Chloro-4-methoxy-5-methylpheny1)-N-[(15)-2-cyclopropyl 1 (3 fluoro-4-methylphenyOethy115-methyl-N- (2-propyny1)-1, 3-thiazol-2-amine hydrochloride (55R125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. Pharmacol Exp. The]: (2002) 301(1)333–345.
   Google Scholar
• GULLY D, GESLIN M, SERVA L et al: 4- (2-Chloro-4-methoxy-5-methylpheny1)-N-[(1S)-2-cyclopropyl 1 (3 fluoro-4-methylphenyl)ethy115-methyl-N- (2-propyny1)-1,3-thiazol-2-amine hydrochloride (55R125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Pharmacol Exp. The]: (2002) 301(1):322–332.
   PubMed Web of Science ®Google Scholar
• KAMALI F: Osanetant sanofi-synthelabo. Carr: Opin. Investig. Drugs (2001) 2 (7):950–956.
   PubMedGoogle Scholar
• BELANOFF JK, FLORES BH, KALEZHAN M, SUND B, SCHATZBERG AF: Rapid reversal of psychotic depression using mifepristone. Clin. Psychopharmacol (2001) 21(5):516–521.
   PubMed Web of Science ®Google Scholar
• BERMAN RM, CAPPIELLO A, ANAND A et al.: Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry (2000) 47:351–354.
   PubMed Web of Science ®Google Scholar
• REUL JM, GESING A, DROSTE S, STEC IS, WEBER A, BACHMANN C: The brain mineralocoricoid receptor: greedy for ligand, mysterious in function. Eui: Pharmacol (2000) 405(1-3):235–249.
   PubMed Web of Science ®Google Scholar
• GUO X, DAWSON VL, DAWSON TM: Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Ear: .1. Neurosci. (2001) 13(9):1683–1693.
   Google Scholar
• WALKER MC, SANDER JVV: New anti-epileptic drugs. Expert Opin. Investig. Drugs (1999) 8:1497–1510.
   PubMedGoogle Scholar
• LLOYD KG, ZIVKOVIC B, SCATTON B, MORSELLI PL, BARTHOLINI G: The gabaergic hypothesis of depression. Frog. Neuropsychopharmacol Biol. Psychiatry (1989) 13(3-4):341–351.
   PubMed Web of Science ®Google Scholar
• KAVOUSSI RJ, PANDE AC, THE PAGOCLONE INVESTIGATORS TEAM: Efficacy and Safety of Pagoclone in the Treatment of Panic Disorder. 40th Annual New Clinical Drug Evaluation Unit (NCDELB Meeting, Boca Raton, FL, USA (2000).
   Google Scholar
• PERUCCA E: IDdb Meeting Report. New Anti-epileptic Drugs - Fifth Eilat Conference, Eilat, Israel (2000).
   Google Scholar
• YATHAM LN, KUSUMAKAR V, CALABRESE JR, RAO R, SCARROW G, KROEKER G: Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. I Clin. Psychiatry(2002) 63(4):275–283.
   PubMed Web of Science ®Google Scholar
• MARX CE, BARBACCIA ML, GUIDOTTI A, RUPPRECHT R, MORROW AL: Neurosteroids and pharmacological treatment strategies in schizophrenia depression, and anxiety disorders. Society of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):94S (Abstract).
   Google Scholar
• OZAWA S, KAMIYA HO, TSUZUKI K: Glutamate receptors in the mammalian central nervous system. Frog. Neurobiol. (1998) 54:581–618.
   Google Scholar
• SVEINBJORNSDOTTIR S, SANDER JW, UPTON D et al.: The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. (1993) 16:165–174.
   PubMed Web of Science ®Google Scholar
• DANNHARDT G, KOHL BK: The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curi: Med. Chem. (1998) 5:253–263.
   PubMed Web of Science ®Google Scholar
• SMITH KM, LARIVE LL, ROMANELLI F: Club drugs: methylenedioxymetham-phetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am. j Health Syst. Pharm. (2002) 59(11):1067–1076.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, BOWDEN CL, MCELROY SL et al.: Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am. Psychiatry (1999) 156:1019–1023.
   PubMed Web of Science ®Google Scholar
• KETTER TA, POST RM, THEODORE WH: Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology (1999) 53\(Suppl. 2):553–567.
   Google Scholar
• MARCOTTE D: Use of topiramate, a new anti-epileptic as a mood stabilizer. Affect. Disord. (1998) 50:245–251.
   PubMed Web of Science ®Google Scholar
• IDdb Meeting Report: Nicotinic Acetylcholine Receptors - IBC's Second International Symposium; Advances in Molecular Pharmacology and Drug Development. Annapolis, MD, USA (1999).
   Google Scholar
• HELTON DR, TIZZANO JP, MONN JA, SCHOEPP DD, KALLMAN MJ: Anxiolytic and side-effectprofile of LY354740: a potent, highly selective orally active agonist for group II metabotropic glutamate receptors. Pharmacol Exp. The]: (1998) 284:651–660.
   Google Scholar
• PAN W, BARNKS WA, KASTIN AJ: Permeability of the blood-brain barrier to neurotrophins. Brain Res. (1998) 788:87–94.
   PubMed Web of Science ®Google Scholar
• SAKANE T, PARDRIDGE WM: Carboxyl-directed pegylation of brain derived neurotrophic factor markedly reduced systemic clearance with minimum loss of biologic activity. Pharm. Res. (1997) 14:1085–1091.
   PubMed Web of Science ®Google Scholar
• TODA S, YAMAMOTTO S, TENMYO 0 et al.: A new neuritogenetic compound BU-4514N produced by Microtetraspora sp. Antibiot. (1993) 46:875–883.
   Google Scholar
• MASOUKA Y, SHIN-YA K, FURIHATA K, HAYAKAWA Y, SETO H: A novel substance with TGF- 13 like activity, diheteropeptin produced by a fungus. Diheterospora sp. Antibiot. (1997) 50:1058–1060.
   Google Scholar
• ZHU J, MIX E, WINBLAD B: The antidepressant and anti-inflammatory effects of rolipram in the central nervous system. CNS Drug Rev (2001) 7(4)387–398.
   Google Scholar
• GUO Z, ZHOU D, SCHULTZ PG: Designing small-molecule switches for protein-pprotein interactions. Science (2000) 288:2042–2045.
   PubMed Web of Science ®Google Scholar
• MANEV RM, MANEV UZ T, MANEV H: Glia, S100B, and antidepressants. Society of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):124S (Abstract).
   Google Scholar
• NEMETS B, STAHL Z, BELMAKER RH: Addiction of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. Psychiatry (2002) 159(3):477–479.
   PubMed Web of Science ®Google Scholar
• PEET M, HORROBIN DF: A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry (2002) 59(10913–919.
   Google Scholar
• STOLL AL, SEVERUS WE, FREEMAN MP et al.: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry(1999) 56(5):407–412.
   PubMed Web of Science ®Google Scholar
• SHYTLE RD, LUKAS RJ, SILVER AA et al: Effects of monoamine depletion on immune parameters in remitted depressed patients. Socieg, of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):1795 (Abstract).
   Google Scholar
• FERGUSON SM, BRODKIN JD, LLOYD GK, MENAGHI F: Antidepressant-like effects of the subtype-selective nichotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmaoclogy (Berl) (2000) 152(3):295–303.
   PubMed Web of Science ®Google Scholar
• COSFORD ND, BLEICHER L, VERNIER JM, CHAVEZ-NORIEGA L, RAO TS, SIEGEL RS: Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated icon channel (nAChR) agonist. Pharm. Acta. Hely. (2000) 74(2-3):125–130.
   PubMedGoogle Scholar
• SCHREIBER R, DALMUS M, DEVRY J: Effects of alpha 4/beta 2- and alpha 7 - nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl) (2002) 159(3):248–257.
   PubMed Web of Science ®Google Scholar
• MINER CM, BROWN EB, GONZALES JS, MUNIR R: Switching from daily SSRIs to fluoxetine once-weekly. Society of Biological Psychiatry 57th Annual Convention and Scientific Program, Philadelphia, USA (2002):179S (Abstract).
   Google Scholar
• SLOMAN L, GILLBERT P (Eds): Subordination and social defeat: An evolutionary approach to mood disorders and their therapy Lawrence Erlbaum Associates, Inc., Mahwah, NJ, US (2000).
   Google Scholar
• YAMADA M, HIGUCHI T: Functional genomics and depression research. Beyond the monoamine hypothesis. Eur. Neuropsychopharmacol. (2002) 12(3):235–244.
   PubMed Web of Science ®Google Scholar